Skip to main content

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Sep 05, 2019 11:48 pm

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

  1. Study of 89 patients with unclassified mono or oligoarthritis shows that the addition of dual energy CT (DECT) scans add little to the diagnosis of those having gout. https://buff.ly/2MWB25t 
  2. Study of 1/2 billion Europeans shows a significant increase in mortality with 2 drinks or more per day of sugar- and artificially sweetened soft drinks; sweetened with digestive deaths (HR 1.59); artifically sweetened with circulatory deaths (HR 1.52). https://t.co/P0JRgaz7oJ
  3. Cochrane review shows there are very few studies addressing whether smoking cessation leads to improvement in RA or inflammatory arthritis. 2 identified studies (57 pts only) failed to examine if smoking cessation intervention reduced disease activity https://t.co/TAJuGD0acc
  4. A prospecitve cohort study of 278 axSpA patients, grouped them into alcohol drinkers and non-drinkers. Alcohol was associated with spinal progression (mSASSS changes ≥ 2 units over 2 yrs) (60.7% vs 29.2%, P https://t.co/XdPrAWPQVG
  5. Observational study of 601 systemic sclerosis patients; 448 Rx with vasodilators (CCB, ACEi, ARBs) & 153 did not. 1) vasodilator therapy was assoc w/ lower risk of vent, arrhythmias (p=.03); 2) low-dose ASA had fewer cardiac blocks & pacemakers (p=.02) https://t.co/mgOcW1Bidd 
  6. Drug use by SLE patients during 376 pregnancies (284 women) was studied. HCQ was used in 24.2%, but was discontinued 17% in the year prior, 30% in 1st trimester, 10% in 2nd trimester & 26% in 3rd trimester. Education on utility of HCQ during Pred needed! https://t.co/SxQW8vpjVO
  7. Anifrolumab (anti-IFNa) was shown to be effective in its 2nd phase III trial in SLE - meeting its primary (BiCLA) endpoint at week 52, according to an Astra-Zeneca press release. Full data to be presented at an upcoming medical meeting. https://t.co/SLaQHJS6WY
  8. Positive safety and efficacy results for subcutaneous infliximab biosimilar, CT-P13 (Remsima), was presented at EULAR 2019. In 48 RA pts, efficacy (DAS28,, ACR20) of CT-P13 SC was comparable to CT-P13-IV up to Week 54. https://t.co/84ismy7ci2
  9. Tocilizumab Shows No Increase in Cardiovascular Risk  
  10. Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA) 
  11. ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Disclosures
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×